Poor Response to Nusinersen May Predict Benefit From Onasemnogene Abeparvovec
Patients with spinal muscular atrophy (SMA) who respond poorly to nusinersen may respond the most favorably to onasemnogene abeparvovec, according to a new study published in Gene Therapy. Alternatively, the age of the patient at the time treatment is started may influence his or her response to onasemnogene abeparvovec. These hypotheses must be tested in…